Search

Your search keyword '"Koffijberg, Hendrik"' showing total 716 results
Start Over Author "Koffijberg, Hendrik"
716 results on '"Koffijberg, Hendrik"'

36. A direct comparison in diagnostic performance of CDUS, FDG-PET/CT and MRI in patients suspected of giant cell arteritis

Author

van Nieuwland, Marieke, primary, Colin, Edgar M, additional, Vermeer, Marloes, additional, Wagenaar, Nils R L, additional, Vijlbrief, Onno D, additional, van Zandwijk, Jordy K, additional, Slart, Riemer H J A, additional, Koffijberg, Hendrik, additional, Jebbink, Erik Groot, additional, van der Geest, Kornelis S M, additional, Brouwer, Elisabeth, additional, Boumans, Dennis, additional, and Alves, Celina, additional

Published
2024
Full Text
View/download PDF

39. Diagnostic yield of a proactive strategy for early detection of cardiovascular disease versus usual care in adults with type 2 diabetes or chronic obstructive pulmonary disease in primary care in the Netherlands (RED-CVD):a multicentre, pragmatic, cluster-randomised, controlled trial

Author

Groenewegen, Amy, Zwartkruis, Victor W., Rienstra, Michiel, Zuithoff, Nicolaas P.A., Hollander, Monika, Koffijberg, Hendrik, Oude Wolcherink, Martijn, Cramer, Maarten J., van der Schouw, Yvonne T., Hoes, Arno W., Rutten, Frans H., de Boer, Rudolf A., Groenewegen, Amy, Zwartkruis, Victor W., Rienstra, Michiel, Zuithoff, Nicolaas P.A., Hollander, Monika, Koffijberg, Hendrik, Oude Wolcherink, Martijn, Cramer, Maarten J., van der Schouw, Yvonne T., Hoes, Arno W., Rutten, Frans H., and de Boer, Rudolf A.

Abstract

Background: Progressive cardiovascular diseases (eg, heart failure, atrial fibrillation, and coronary artery disease) are often diagnosed late in high-risk individuals with common comorbidities that might mimic or mask symptoms, such as chronic obstructive pulmonary disease (COPD) and type 2 diabetes. We aimed to assess whether a proactive diagnostic strategy consisting of a symptom and risk factor questionnaire and low-cost and accessible tests could increase diagnosis of progressive cardiovascular diseases in patients with COPD or type 2 diabetes in primary care. Methods:In this multicentre, pragmatic, cluster-randomised, controlled trial (RED-CVD), 25 primary care practices in the Netherlands were randomly assigned to usual care or a proactive diagnostic strategy conducted during routine consultations and consisting of a validated symptom questionnaire, followed by physical examination, N-terminal-pro-B-type natriuretic peptide measurement, and electrocardiography. We included adults (≥18 years) with type 2 diabetes, COPD, or both, who participated in a disease management programme. Patients with an established triple diagnosis of heart failure, atrial fibrillation, and coronary artery disease were excluded. In the case of abnormal findings, further work-up or treatment was done at the discretion of the general practitioner. The primary endpoint was the number of newly diagnosed cases of heart failure, atrial fibrillation, and coronary artery disease, adjudicated by an expert clinical outcome committee using international guidelines, at 1-year follow-up, in the intention-to-treat population. Findings: Between Jan 31, 2019, and Oct 7, 2021, we randomly assigned 25 primary care centres: 11 to usual care and 14 to the intervention. We included patients between June 21, 2019, and Jan 31, 2022. Following exclusion of ineligible patients and those who did not give informed consent, 1216 participants were includ

Published
2024

40. Comparing modeling strategies combining changes in multiple serum tumor biomarkers for early prediction of immunotherapy non-response in non-small cell lung cancer

Author

van Delft, Frederik A, Schuurbiers, Milou M F, Muller, Mirte, Burgers, Sjaak A, van Rossum, Huub H, IJzerman, Maarten J, van den Heuvel, Michel M, Koffijberg, Hendrik, van Delft, Frederik A, Schuurbiers, Milou M F, Muller, Mirte, Burgers, Sjaak A, van Rossum, Huub H, IJzerman, Maarten J, van den Heuvel, Michel M, and Koffijberg, Hendrik

Abstract

BACKGROUND: Patients treated with immune checkpoint inhibitors (ICI) are at risk of adverse events (AEs) even though not all patients will benefit. Serum tumor markers (STMs) are known to reflect tumor activity and might therefore be useful to predict response, guide treatment decisions and thereby prevent AEs.OBJECTIVE: This study aims to compare a range of prediction methods to predict non-response using multiple sequentially measured STMs.METHODS: Nine prediction models were compared to predict treatment non-response at 6-months (n = 412) using bi-weekly CYFRA, CEA, CA-125, NSE, and SCC measurements determined in the first 6-weeks of therapy. All methods were applied to six different biomarker combinations including two to five STMs. Model performance was assessed based on sensitivity, while model training aimed at 95% specificity to ensure a low false-positive rate.RESULTS: In the validation cohort, boosting provided the highest sensitivity at a fixed specificity across most STM combinations (12.9% -59.4%). Boosting applied to CYFRA and CEA achieved the highest sensitivity on the validation data while maintaining a specificity >95%.CONCLUSIONS: Non-response in NSCLC patients treated with ICIs can be predicted with a specificity >95% by combining multiple sequentially measured STMs in a prediction model. Clinical use is subject to further external validation.

Published
2024

41. Diagnostic yield of a proactive strategy for early detection of cardiovascular disease versus usual care in adults with type 2 diabetes or chronic obstructive pulmonary disease in primary care in the Netherlands (RED-CVD): a multicentre, pragmatic, cluster-randomised, controlled trial

Author

HAG Hart- Vaatziekten, Biostatistiek Onderzoek, Other research (not in main researchprogram), HAG Zorginnovatieonderzoek, Circulatory Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Team Medisch, Cardiovasculaire Epi Team 1, Directie Raad van Bestuur, Groenewegen, Amy, Zwartkruis, Victor W, Rienstra, Michiel, Zuithoff, Nicolaas P A, Hollander, Monika, Koffijberg, Hendrik, Oude Wolcherink, Martijn, Cramer, Maarten J, van der Schouw, Yvonne T, Hoes, Arno W, Rutten, Frans H, de Boer, Rudolf A, HAG Hart- Vaatziekten, Biostatistiek Onderzoek, Other research (not in main researchprogram), HAG Zorginnovatieonderzoek, Circulatory Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Team Medisch, Cardiovasculaire Epi Team 1, Directie Raad van Bestuur, Groenewegen, Amy, Zwartkruis, Victor W, Rienstra, Michiel, Zuithoff, Nicolaas P A, Hollander, Monika, Koffijberg, Hendrik, Oude Wolcherink, Martijn, Cramer, Maarten J, van der Schouw, Yvonne T, Hoes, Arno W, Rutten, Frans H, and de Boer, Rudolf A

Published
2024

42. Simulating Progression-Free and Overall Survival for First-Line Doublet Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients Based on Real-World Registry Data

Author

Degeling, Koen, Wong, Hui-Li, Koffijberg, Hendrik, Jalali, Azim, Shapiro, Jeremy, Kosmider, Suzanne, Wong, Rachel, Lee, Belinda, Burge, Matthew, Tie, Jeanne, Yip, Desmond, Nott, Louise, Khattak, Adnan, Lim, Stephanie, Caird, Susan, Gibbs, Peter, and IJzerman, Maarten

Published
2020
Full Text
View/download PDF

49. Willingness to participate in combination screening for lung cancer, chronic obstructive pulmonary disease and cardiovascular disease in four European countries

Author

Behr, Carina, primary, Koffijberg, Hendrik, additional, IJzerman, Maarten, additional, Kauczor, Hans-Ulrich, additional, Revel, Marie-Pierre, additional, Silva, Mario, additional, von Stackelberg, Oyunbileg, additional, van Til, Janine, additional, and Vliegenthart, Rozemarijn, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results